Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2023 | Highlights in gynecological cancers at ESMO 2023

Mansoor Raza Mizra • 22 Oct 2023
ESMO 2023
Cervical Cancer Endometrial Cancer Ovarian Cancer Dostarlimab Paclitaxel Pembrolizumab Tisotumab Vedotin
AtTEnd innovaTV 301 INTERLACE KEYNOTE-826

Mansoor Raza Mizra, MD, Copenhagen University Hospital, Copenhagen, Denmark discusses the recent findings of clinical trials in gynecological cancers, including ovarian, cervical and endometrial malignancies. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Mansoor Raza Mizra

5:01
Dostarlimab + chemo in pA/rEC: PFS & OS by molecular classification in ENGOT-EN6-NSGO/GOG-3031/RUBY
Mansoor Raza Mizra • 22 Oct 2023

Related Videos

0:39
Early diagnosis of ovarian cancer with Pap smears
Sergio Marchini • 8 Apr 2024
0:46
FRa expression and sequencing ADCs in endometrial cancer
Rebecca Porter • 8 Apr 2024
4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
1:11
Clonal hematopoiesis mutations in ovarian carcinomas
Rebecca Porter • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals